Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 462 clinical trials
Acute Promyelocytic Leukemia 2006 (APL)

To assess the role of Arsenic trioxide and/or ATRA during consolidation course in APL. It is hoped that the investigational arms will further increase the event-free survival at 2 years, with reduced toxicity and without increasing the relapse rate by comparison with a classical anthracycline-AraC consolidation regimen.

tretinoin
anthracyclines
idarubicin
arsenic
  • 13 views
  • 07 Nov, 2020
  • 1 location
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

refractory acute myeloid leukemia (aml)
secondary acute myeloid leukemia
serum bilirubin level
mitoxantrone
  • 15 views
  • 07 Nov, 2020
  • 1 location
Cladribine Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.

cytarabine
remission
idarubicin
cladribine
  • 14 views
  • 07 Nov, 2020
  • 1 location
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

The investigators hypothesize that MGD006 for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with MGD006 will be safe, tolerable and may …

  • 0 views
  • 31 May, 2021
  • 1 location
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2

The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).

remission
graft versus host disease
  • 17 views
  • 07 Nov, 2020
  • 1 location
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

Quizartinib, a selective FLT3 inhibitor, is being developed as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The absolute oral bioavailability of quizartinib

  • 0 views
  • 13 May, 2021
  • 1 location
Azacitidine and Homoharringtonine in JMML

, which exhibited a anticancer mechanism and has been widely used in patients with relapse/refractory acute myeloid leukemia (AML). However, the efficacy of these agents has not been elucidated in

refractory acute myeloid leukemia (aml)
azacitidine
myeloid leukemia
  • 0 views
  • 25 Jan, 2021
  • 1 location
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients ( 60) With Acute Myeloid Leukemia

In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual patients must be individualized. One of the tools for this is molecular-cytogenetic stratification

cladribine
colony stimulating factor
adult acute myelogenous leukemia
ara-c
filgrastim
  • 19 views
  • 08 Nov, 2020
  • 1 location
Study of Magrolimab Combinations in Participants With Myeloid Malignancies

therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone, etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants with acute myeloid leukemia (AML

  • 0 views
  • 07 Jun, 2021
  • 1 location